Assessing outcome differences in the second line treatment of metastatic colorectal cancer (mCRC): An ARCAD analysis comparing sequence after first line trials (SAFL) and dedicated second line trials (DSLT).
Alexis D. Leal(Mayo Clinic in Arizona), Axel Grothey(Campbell Clinic), Daniel J. Sargent(National Institute of Agricultural Botany), Marc Peeters(University of Antwerp), Cornelis J.A. Punt(Utrecht University), Levi Pederson(Mayo Clinic in Florida), Aimery de Gramont(Institut Hospitalier Franco Britannique), Fang‐Shu Ou(Mayo Clinic), Bruce J. Giantonio(Northwestern University), Shaheenah Dawood(Mediclinic City Hospital), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Alberto F. Sobrero(Ospedale Policlinico San Martino), Mace L. Rothenberg(Vanderbilt University), Dirk Arnold(Asklepios Klinik Altona), Henry C. Pitot(Mayo Clinic), Christophe Tournigand(Université Paris-Est Créteil)
Cited by 0
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k